Epigenetic changes during disease progression in a murine model of human chronic lymphocytic leukemia

Shih Shih Chen, Aparna Raval, Amy J. Johnson, Erin Hertlein, Te Hui Liua, Victor X. Jin, Mara Sherman, Shu Jun Liu, David W. Dawson, Katie E. Williams, Mark Lanasa, Sandya Liyanarachchi, Thomas S. Lin, Guido Marcucci, Yuri Pekarsky, Ramana Davuluri, Carlo M. Croce, Denis C. Guttridge, Michael A. Teitell, John C. Byrd & 1 others Christoph Plass

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

Epigenetic alterations, including gain or loss of DNA methylation, are a hallmark of nearly every malignancy. Changes in DNA methylation can impact expression of cancer-related genes including apoptosis regulators and tumor suppressors. Because such epigenetic changes are reversible, they are being aggressively investigated as potential therapeutic targets. Here we use the Eμ-TCL1 transgenic mouse model of chronic lymphocytic leukemia (CLL) to determine the timing and patterns of aberrant DNA methylation, and to investigate the mechanisms that lead to aberrant DNA methylation. We show that CLL cells from Eμ-TCL1 mice at various stages recapitulate epigenetic alterations seen in human CLL. Aberrant methylation of promoter sequences is observed as early as 3 months of age in these animals, well before disease onset. Abnormally methylated promoter regions include binding sites for the transcription factor FOXD3. We show that loss of Foxd3 expression due to an NF-κB p50/p50:HDAC1 repressor complex occurs in TCL1-positive B cells before methylation. Therefore, specific transcriptional repression is an early event leading to epigenetic silencing of target genes in murine and human CLL. These results provide strong rationale for the development of strategies to target NF-κB components in CLL and potentially other B-cell malignancies.

Original languageEnglish (US)
Pages (from-to)13433-13438
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume106
Issue number32
DOIs
StatePublished - Aug 11 2009
Externally publishedYes

Fingerprint

B-Cell Chronic Lymphocytic Leukemia
Epigenomics
Disease Progression
DNA Methylation
Methylation
B-Lymphocytes
Neoplasms
Neoplasm Genes
Gene Silencing
Genetic Promoter Regions
Transgenic Mice
Transcription Factors
Binding Sites
Apoptosis

Keywords

  • CLL
  • DNA methylation
  • Epigenetics
  • FOXD3

ASJC Scopus subject areas

  • General

Cite this

Epigenetic changes during disease progression in a murine model of human chronic lymphocytic leukemia. / Chen, Shih Shih; Raval, Aparna; Johnson, Amy J.; Hertlein, Erin; Liua, Te Hui; Jin, Victor X.; Sherman, Mara; Liu, Shu Jun; Dawson, David W.; Williams, Katie E.; Lanasa, Mark; Liyanarachchi, Sandya; Lin, Thomas S.; Marcucci, Guido; Pekarsky, Yuri; Davuluri, Ramana; Croce, Carlo M.; Guttridge, Denis C.; Teitell, Michael A.; Byrd, John C.; Plass, Christoph.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 106, No. 32, 11.08.2009, p. 13433-13438.

Research output: Contribution to journalArticle

Chen, SS, Raval, A, Johnson, AJ, Hertlein, E, Liua, TH, Jin, VX, Sherman, M, Liu, SJ, Dawson, DW, Williams, KE, Lanasa, M, Liyanarachchi, S, Lin, TS, Marcucci, G, Pekarsky, Y, Davuluri, R, Croce, CM, Guttridge, DC, Teitell, MA, Byrd, JC & Plass, C 2009, 'Epigenetic changes during disease progression in a murine model of human chronic lymphocytic leukemia', Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 32, pp. 13433-13438. https://doi.org/10.1073/pnas.0906455106
Chen, Shih Shih ; Raval, Aparna ; Johnson, Amy J. ; Hertlein, Erin ; Liua, Te Hui ; Jin, Victor X. ; Sherman, Mara ; Liu, Shu Jun ; Dawson, David W. ; Williams, Katie E. ; Lanasa, Mark ; Liyanarachchi, Sandya ; Lin, Thomas S. ; Marcucci, Guido ; Pekarsky, Yuri ; Davuluri, Ramana ; Croce, Carlo M. ; Guttridge, Denis C. ; Teitell, Michael A. ; Byrd, John C. ; Plass, Christoph. / Epigenetic changes during disease progression in a murine model of human chronic lymphocytic leukemia. In: Proceedings of the National Academy of Sciences of the United States of America. 2009 ; Vol. 106, No. 32. pp. 13433-13438.
@article{0666a394301c4714b7b85ca8d6bb35bb,
title = "Epigenetic changes during disease progression in a murine model of human chronic lymphocytic leukemia",
abstract = "Epigenetic alterations, including gain or loss of DNA methylation, are a hallmark of nearly every malignancy. Changes in DNA methylation can impact expression of cancer-related genes including apoptosis regulators and tumor suppressors. Because such epigenetic changes are reversible, they are being aggressively investigated as potential therapeutic targets. Here we use the Eμ-TCL1 transgenic mouse model of chronic lymphocytic leukemia (CLL) to determine the timing and patterns of aberrant DNA methylation, and to investigate the mechanisms that lead to aberrant DNA methylation. We show that CLL cells from Eμ-TCL1 mice at various stages recapitulate epigenetic alterations seen in human CLL. Aberrant methylation of promoter sequences is observed as early as 3 months of age in these animals, well before disease onset. Abnormally methylated promoter regions include binding sites for the transcription factor FOXD3. We show that loss of Foxd3 expression due to an NF-κB p50/p50:HDAC1 repressor complex occurs in TCL1-positive B cells before methylation. Therefore, specific transcriptional repression is an early event leading to epigenetic silencing of target genes in murine and human CLL. These results provide strong rationale for the development of strategies to target NF-κB components in CLL and potentially other B-cell malignancies.",
keywords = "CLL, DNA methylation, Epigenetics, FOXD3",
author = "Chen, {Shih Shih} and Aparna Raval and Johnson, {Amy J.} and Erin Hertlein and Liua, {Te Hui} and Jin, {Victor X.} and Mara Sherman and Liu, {Shu Jun} and Dawson, {David W.} and Williams, {Katie E.} and Mark Lanasa and Sandya Liyanarachchi and Lin, {Thomas S.} and Guido Marcucci and Yuri Pekarsky and Ramana Davuluri and Croce, {Carlo M.} and Guttridge, {Denis C.} and Teitell, {Michael A.} and Byrd, {John C.} and Christoph Plass",
year = "2009",
month = "8",
day = "11",
doi = "10.1073/pnas.0906455106",
language = "English (US)",
volume = "106",
pages = "13433--13438",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "32",

}

TY - JOUR

T1 - Epigenetic changes during disease progression in a murine model of human chronic lymphocytic leukemia

AU - Chen, Shih Shih

AU - Raval, Aparna

AU - Johnson, Amy J.

AU - Hertlein, Erin

AU - Liua, Te Hui

AU - Jin, Victor X.

AU - Sherman, Mara

AU - Liu, Shu Jun

AU - Dawson, David W.

AU - Williams, Katie E.

AU - Lanasa, Mark

AU - Liyanarachchi, Sandya

AU - Lin, Thomas S.

AU - Marcucci, Guido

AU - Pekarsky, Yuri

AU - Davuluri, Ramana

AU - Croce, Carlo M.

AU - Guttridge, Denis C.

AU - Teitell, Michael A.

AU - Byrd, John C.

AU - Plass, Christoph

PY - 2009/8/11

Y1 - 2009/8/11

N2 - Epigenetic alterations, including gain or loss of DNA methylation, are a hallmark of nearly every malignancy. Changes in DNA methylation can impact expression of cancer-related genes including apoptosis regulators and tumor suppressors. Because such epigenetic changes are reversible, they are being aggressively investigated as potential therapeutic targets. Here we use the Eμ-TCL1 transgenic mouse model of chronic lymphocytic leukemia (CLL) to determine the timing and patterns of aberrant DNA methylation, and to investigate the mechanisms that lead to aberrant DNA methylation. We show that CLL cells from Eμ-TCL1 mice at various stages recapitulate epigenetic alterations seen in human CLL. Aberrant methylation of promoter sequences is observed as early as 3 months of age in these animals, well before disease onset. Abnormally methylated promoter regions include binding sites for the transcription factor FOXD3. We show that loss of Foxd3 expression due to an NF-κB p50/p50:HDAC1 repressor complex occurs in TCL1-positive B cells before methylation. Therefore, specific transcriptional repression is an early event leading to epigenetic silencing of target genes in murine and human CLL. These results provide strong rationale for the development of strategies to target NF-κB components in CLL and potentially other B-cell malignancies.

AB - Epigenetic alterations, including gain or loss of DNA methylation, are a hallmark of nearly every malignancy. Changes in DNA methylation can impact expression of cancer-related genes including apoptosis regulators and tumor suppressors. Because such epigenetic changes are reversible, they are being aggressively investigated as potential therapeutic targets. Here we use the Eμ-TCL1 transgenic mouse model of chronic lymphocytic leukemia (CLL) to determine the timing and patterns of aberrant DNA methylation, and to investigate the mechanisms that lead to aberrant DNA methylation. We show that CLL cells from Eμ-TCL1 mice at various stages recapitulate epigenetic alterations seen in human CLL. Aberrant methylation of promoter sequences is observed as early as 3 months of age in these animals, well before disease onset. Abnormally methylated promoter regions include binding sites for the transcription factor FOXD3. We show that loss of Foxd3 expression due to an NF-κB p50/p50:HDAC1 repressor complex occurs in TCL1-positive B cells before methylation. Therefore, specific transcriptional repression is an early event leading to epigenetic silencing of target genes in murine and human CLL. These results provide strong rationale for the development of strategies to target NF-κB components in CLL and potentially other B-cell malignancies.

KW - CLL

KW - DNA methylation

KW - Epigenetics

KW - FOXD3

UR - http://www.scopus.com/inward/record.url?scp=69449100327&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=69449100327&partnerID=8YFLogxK

U2 - 10.1073/pnas.0906455106

DO - 10.1073/pnas.0906455106

M3 - Article

VL - 106

SP - 13433

EP - 13438

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 32

ER -